Business Description
Cocrystal Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US19188J4094
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.94 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.1 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | 11.2 | |||||
3-Year Book Growth Rate | -33.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | -8.44 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 68.27 | |||||
9-Day RSI | 61.74 | |||||
14-Day RSI | 58.54 | |||||
6-1 Month Momentum % | -15.04 | |||||
12-1 Month Momentum % | 17.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.32 | |||||
Quick Ratio | 7.32 | |||||
Cash Ratio | 6.68 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.1 | |||||
Shareholder Yield % | -5.94 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -85.2 | |||||
ROA % | -72.93 | |||||
ROIC % | -903.73 | |||||
ROC (Joel Greenblatt) % | -1204.01 | |||||
ROCE % | -87.52 |
GF Value Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.15 | |||||
Price-to-Tangible-Book | 2.16 | |||||
EV-to-EBIT | -0.8 | |||||
EV-to-EBITDA | -0.81 | |||||
EV-to-FCF | -0.97 | |||||
Price-to-Net-Current-Asset-Value | 2.55 | |||||
Price-to-Net-Cash | 2.88 | |||||
Earnings Yield (Greenblatt) % | -125 | |||||
FCF Yield % | -61.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cocrystal Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.695 | ||
Beta | 0.85 | ||
Volatility % | 66.12 | ||
14-Day RSI | 58.54 | ||
14-Day ATR (€) | 0.062612 | ||
20-Day SMA (€) | 1.8865 | ||
12-1 Month Momentum % | 17.79 | ||
52-Week Range (€) | 1.28 - 2.54 | ||
Shares Outstanding (Mil) | 10.17 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cocrystal Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cocrystal Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cocrystal Pharma Inc Frequently Asked Questions
What is Cocrystal Pharma Inc(FRA:8CC)'s stock price today?
When is next earnings date of Cocrystal Pharma Inc(FRA:8CC)?
Does Cocrystal Pharma Inc(FRA:8CC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |